ProSomnus Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John Remmers is an accomplished physician, scientist, educator, innovator, and pioneer in the field of sleep medicine

Dr. John E. Remmers, MD has been appointed to the ProSomnus Sleep Technologies leadership team. ProSomnus Sleep Technologies is the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea.

This move underscores ProSomnus’s commitment to accelerating the development of Oral Appliance Therapy as a safe, effective, and patient-preferred treatment option for the one billion people worldwide who suffer from OSA.

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

“Millions of people around the world breathe better in their sleep thanks to the myriad contributions of Dr. John Remmers,” noted Len Liptak, CEO. “John is a pioneer in the research, medical education, clinical practice and technologies integral to the diagnosis and management of OSA. ProSomnus is honored to work with John to further develop ProSomnus Oral Appliance Therapy devices as a leading treatment option.”

“Joining ProSomnus is one of the greatest opportunities of my career. ProSomnus is already the leader in the digital manufacturing of oral appliances for sleep apnea, the company is now undertaking new approaches that will engage my expertise and background in the field. I look forward with great anticipation to partnering with ProSomnus to improve the treatment of sleep apnea,” stated John E. Remmers, MD.

Dr. Remmers is a world-renowned expert in the field of snoring and sleep apnea, being the first researcher to elucidate the pathogenesis of sleep apnea and to demonstrate that sleep apnea is caused by an anatomical narrowing of the pharynx. As a recognized pioneer and innovator in sleep medicine, Dr. Remmers has invented products ranging from portable diagnostic sleep monitors to auto-titrating CPAP devices, including proactive algorithms to automatically adjust CPAP pressure based on patient need.

Dr. Remmers served two terms as the Editor-in-Chief of the Journal of Applied Physiology and has presented honorary research lectures to the American Thoracic Society, the American Physiological Society and American College of Chest Physicians. His research interests relate to the neurobiology of respiratory rhythmogenesis, chemoreception, and the pathophysiology of the control of breathing. Dr. Remmers has published over 100 peer-reviewed publications in the area of respiratory physiology. An accomplished physician, John founded the Foothills Medical Centre and Sleep Lab in Calgary and was clinical professor of internal medicine at the University of Calgary, where he is still actively involved with several programs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”